Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2009, Article ID 406965, 7 pages
http://dx.doi.org/10.1155/2009/406965
Clinical Study

The Impact of Multiple Malignancies on Patients with Bladder Carcinoma: A Population-Based Study Using the SEER Database

Department of Urology, New York Presbyterian Hospital, Weill Medical College of Cornell University, 525 East 68th Street, Starr 900, New York, NY 10021, USA

Received 8 July 2009; Accepted 23 October 2009

Academic Editor: Badrinath Konety

Copyright © 2009 Joshua R. Ehrlich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. F. Fraumeni Jr., R. E. Curtis, B. K. Edwards, and M. A. Tucker, “Introduction,” in New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973–2000, R. E. Curtis, D. M. Friedman, E. Ron et al., Eds., pp. 1–8, National Cancer Institute, Bethesda, Md, USA, 2006, NIH Publ. No. 05-5302. View at Google Scholar
  2. A. B. Mariotto, J. H. Rowland, L. A. G. Ries, S. Scoppa, and E. J. Feuer, “Multiple cancer prevalence: a growing challenge in long-term survivorship,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 3, pp. 566–571, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. D. L. Lamm, B. A. Blumenstein, J. D. Crissman et al., “Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study,” Journal of Urology, vol. 163, no. 4, pp. 1124–1129, 2000. View at Google Scholar · View at Scopus
  4. H. W. Herr, D. M. Schwalb, Z.-F. Zhang et al., “Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial,” Journal of Clinical Oncology, vol. 13, no. 6, pp. 1404–1408, 1995. View at Google Scholar · View at Scopus
  5. A. Bisiaux, N. Thiounn, M.-O. Timsit et al., “Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus Calmette-Guerin therapy in patients with superficial bladder cancer,” Journal of Urology, vol. 181, no. 4, pp. 1571–1580, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. Y.-H. Gan, R. Mahendran, K. James, C. Lawrencia, and K. Esuvaranathan, “Evaluation of lymphocytic responses after treatment with bacillus Calmette-Guerin and interferon-α 2b for superficial bladder cancer,” Clinical Immunology, vol. 90, no. 2, pp. 230–237, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. G. Klein and E. Klein, “Surveillance against tumors—is it mainly immunological?” Immunology Letters, vol. 100, no. 1, pp. 29–33, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. A. K. Ng and L. B. Travis, “Subsequent malignant neoplasms in cancer survivors,” Cancer Journal, vol. 14, no. 6, pp. 429–434, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, “Cancer immunoediting: from immunosurveillance to tumor escape,” Nature Immunology, vol. 3, no. 11, pp. 991–998, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. L. A. Levine and J. P. Richie, “Urological complications of cyclophosphamide,” Journal of Urology, vol. 141, no. 5, pp. 1063–1069, 1989. View at Google Scholar · View at Scopus
  11. S. Boorjian, J. E. Cowan, B. R. Konety et al., “Bladder cancer incidence and risk factors in men with prostate cancer: results from cancer of the prostate strategic urologic research endeavor,” Journal of Urology, vol. 177, no. 3, pp. 883–888, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. J. S. Sandhu, A. J. Vickers, B. Bochner, S. M. Donat, H. W. Herr, and G. Dalbagni, “Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer,” BJU International, vol. 98, no. 1, pp. 59–62, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. P. J. Bostrom, M. S. Soloway, M. Manoharan, R. Ayyathurai, and S. Samavedi, “Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy,” Journal of Urology, vol. 179, no. 1, pp. 91–95, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. K. Moon, G. J. Stukenborg, J. Keim, and D. Theodorescu, “Cancer incidence after localized therapy for prostate cancer,” Cancer, vol. 107, no. 5, pp. 991–998, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. N. Pabla and Z. Dong, “Cisplatin nephrotoxicity: mechanisms and renoprotective strategies,” Kidney International, vol. 73, no. 9, pp. 994–1007, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. M. de Forni and J.-P. Armand, “Cardiotoxicity of chemotherapy,” Current Opinion in Oncology, vol. 6, no. 4, pp. 340–344, 1994. View at Google Scholar · View at Scopus
  17. C. S. J. Duchateau and M. P. M. Stokkel, “Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival,” Chest, vol. 127, no. 4, pp. 1152–1158, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus